Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease
Top Cited Papers
- 15 March 2017
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 195 (6), 814-823
- https://doi.org/10.1164/rccm.201604-0700oc
Abstract
Rationale Lengthy multi-drug, toxic, and low efficacy regimens limit management of pulmonary nontuberculous mycobacterial (PNTM) disease. Objective This phase 2 study investigated efficacy and safety of liposomal amikacin for inhalation (LAI) in treatment-refractory PNTM (Mycobacterium avium complex [MAC] or Mycobacterium abscessus) disease. Methods During the double-blind phase, patients were randomly assigned to LAI (590 mg) or placebo once daily added to their multi-drug regimen for 84 days. Both groups could receive open-label LAI for 84 additional days. Primary endpoint was change from baseline to day 84 on a semi-quantitative mycobacterial growth scale. Other endpoints included sputum conversion, 6-minute walk distance, and adverse events. Measurements and Main Results Modified intent-to-treat population included 89 (LAI=44; placebo=45) patients. Average age was 59 years, 88% were female, 92% were Caucasian; 80 and 59 patients completed study drug dosing during the double-blind and open-label phases, respectively. Primary endpoint was not achieved (P=0.072); however, a greater proportion of the LAI group demonstrated ≥1 negative sputum cultures (32% [14/44] vs. 9% [4/45]; P=0.006) and improvement in 6-minute walk test (+20.6 vs. −25.0 meters; P=0.017) at day 84. Treatment effect was predominantly in patients without cystic fibrosis with MAC and was sustained 1 year post-LAI. Most adverse events were respiratory and in some patients led to drug discontinuation. Conclusions Although the primary endpoint was not reached, LAI added to a multi-drug regimen produced improvements in sputum conversion and 6-minute walk distance vs. placebo with limited systemic toxicity in patients with refractory MAC lung disease. Further research is needed. Clinical trial registration available at www.clinicaltrials.gov, ID NCT01315236.Keywords
This publication has 28 references indexed in Scilit:
- Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010Emerging Infectious Diseases, 2013
- Phase II studies of nebulised Arikace in CF patients withPseudomonas aeruginosainfectionThorax, 2013
- Lung Manifestations in an Autopsy-Based Series of Pulmonary or Disseminated Nontuberculous Mycobacterial DiseaseSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Prevalence of Nontuberculous Mycobacterial Lung Disease in U.S. Medicare BeneficiariesAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal InfectionAntimicrobial Agents and Chemotherapy, 2009
- Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The NetherlandsThorax, 2009
- When and how to treat pulmonary non‐tuberculous mycobacterial diseasesRespirology, 2008
- Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infectionsJournal of Antimicrobial Chemotherapy, 2008
- Aminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial DiseasesClinical Infectious Diseases, 2004
- Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicityAntimicrobial Agents and Chemotherapy, 1989